Patents by Inventor Michael J. Duryee

Michael J. Duryee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230075784
    Abstract: In various embodiments methods of distinguishing Crohn's disease from ulcerative colitis are provided. In certain embodiments the methods comprise determining, or causing to be determined, the level of IgG antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from a mammal, where an elevated level of said antibodies as compared to the average level found in a mammal with Crohn's disease is an indicator that the mammal has ulcerative colitis rather than Crohn's disease.
    Type: Application
    Filed: January 15, 2021
    Publication date: March 9, 2023
    Applicant: Board of Regents of the University of Nebraska
    Inventors: Geoffrey M. Thiele, Amar Singh, Michael J. Duryee, Rizwan Ahmad
  • Patent number: 11542341
    Abstract: In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: January 3, 2023
    Assignee: Board of Regents of The University Of Nebraska
    Inventors: Geoffrey M. Thiele, Daniel R. Anderson, Michael J. Duryee
  • Publication number: 20200249224
    Abstract: In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.
    Type: Application
    Filed: February 4, 2020
    Publication date: August 6, 2020
    Inventors: Geoffrey M. Thiele, Daniel R. Anderson, Michael J. Duryee
  • Patent number: 10591468
    Abstract: In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldheyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 17, 2020
    Assignee: Board of Regents of The University of Nebraska
    Inventors: Geoffrey M. Thiele, Daniel R. Anderson, Michael J. Duryee
  • Publication number: 20140170068
    Abstract: In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.
    Type: Application
    Filed: March 12, 2012
    Publication date: June 19, 2014
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Geoffrey M. Thiele, Daniel R. Anderson, Michael J. Duryee